• Novartis flagged positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis.
• Late-breaking trial data will be presented at MSToronto2026 on Oct. 23, positioning the oral BTK inhibitor as a potential new option.
• Separate late-breaking Phase III NEOS findings on Kesimpta in pediatric multiple sclerosis will also be presented on Oct. 23.
• Additional conference presentations will expand evidence on Kesimpta use in treatment-naive patients, pregnancy, and breastfeeding.
• A virtual investor event is scheduled to discuss the REMODEL readout and remibrutinib’s role in multiple sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070700OMX_____CNEWS_EN_GNW1001276650_en) on October 07, 2026, and is solely responsible for the information contained therein.